Valeant to Syndicate Senior Secured Term Loan Credit Facility
Valeant Pharmaceuticals International, Inc. announced plans to syndicate a $500 million senior secured term loan B credit facility as a new tranche under its existing senior secured credit facilities to fund repayment of its existing $275 million revolving facility and for general corporate purposes, including acquisitions.
The term loan B loans will mature in 2019 and are expected to have terms that are customary for this type of financing. The facility is expected to close in February 2012, subject to market and other customary conditions.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Previously on abfjournal.com: